Synthesis shows urease inhibition in cobalt(II) complexes, suggesting potential therapeutic applications.
New cobalt(II) and copper(I) complexes, [CoCl2(L1)2] (1) and [CuClL2(Ph3P)2]·CH3CN (2), where L1 = 1-(4-bromobenzylidene)thiosemicarbazide, L2 = 1-(2,4-dichlorobenzylidene)thiosemicarbazide, PPh3 = = triphenylphosphine, were synthesized and characterized by elemental analysis and physico-chemical method, as well as single crystal X-ray diffraction. The complexes were also tested for their urease inhibitory properties. The cobalt complex has strong activity (IC50 = 5.7 μM). Enzymatic kinetics research suggested that the cobalt complex is a non-competitive urease inhibitor.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: